India Pharmaceutical Market By Type (Pharmaceutical Drugs (Gynecology Drugs, Respiratory Drugs, Dermatology Drugs, Analgesic Drugs, Oncology Drugs, Others), Biologics (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines)), By Drug Classification (Branded Drugs, Generic Drugs), By Mode of Purchase (Prescription-Based Drugs, Over-the-counter Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Pharmaceutical Market was valued at USD 65.20 Billion in 2024 and is expected to reach USD 106.67 Billion by 2030 with a CAGR of 8.75% during the forecast period.

India’s pharmaceutical market expansion is driven by strong domestic demand and its position as a global manufacturing hub. A growing middle class, rising healthcare awareness, and government initiatives like the Pradhan Mantri Jan Arogya Yojana are improving healthcare access and boosting pharmaceutical consumption across the country.

Globally, India plays a critical role as a supplier of affordable medicines, providing over 60% of the world’s vaccines and around 20% of generic drugs. This leadership is supported by its cost-efficient manufacturing capabilities and strong expertise in generics, enabling it to meet global healthcare needs effectively.

However, the industry faces challenges that could impact future growth. Regulatory complexity under the Central Drugs Standard Control Organization can create compliance hurdles and increase operational costs. Additionally, government-imposed price controls on essential medicines, while improving affordability, may limit profit margins and restrict investment in innovation and R&D. Balancing accessibility with sustainable industry growth remains a key concern.

Key Market Drivers

Growing Prevalence of Chronic Diseases

The Indian pharmaceutical market is being strongly propelled by the rising burden of chronic diseases, as the Government of India has stated that non communicable diseases have become a significant challenge to health and development, while PIB citing the India State Level Disease Burden Initiative noted that the share of deaths linked to these conditions rose from 37.9 percent in 1990 to 61.8 percent in 2016.

This disease transition is steadily expanding demand for long term drug therapy across diabetes, cardiovascular disease, cancer, and chronic respiratory disorders, with WHO noting a rising NCD burden in India and official policy documents showing that NCDs now account for 62 percent of the country’s total disease burden in terms of DALYs. Access remains a major issue because the National Free Drugs Service Initiative states that medicines account for more than 67 percent of out of pocket healthcare spending in India, which is why the government has prioritized free essential generic medicines in public facilities through the NHM framework.

For instance, Sun Pharma reported total R and D investment of ₹31,775.9 million in FY24, said its specialty business contributed over 18 percent of global turnover, markets 26 specialty products globally, and has six new active substances in clinical development, showing how major pharmaceutical companies are expanding chronic care and specialty portfolios in response to India’s evolving disease profile and long term treatment needs.

Rise in Generic Drug Industry

India’s pharmaceutical industry remains a major force in global healthcare, and the generics segment sits at the center of that strength because India is the world’s largest supplier of generic medicines and accounts for 20 percent of global generic supply by volume. The country manufactures about 60,000 generic brands across 60 therapeutic categories, which helps meet the needs of a price sensitive domestic population while also supporting large scale supply to regulated markets that continue to seek affordable medicines with dependable quality.

This global role has reinforced India’s position as the pharmacy of the world and has encouraged companies to move beyond plain vanilla generics into more complex formulations, injectables, and biosimilars that require stronger technical capabilities and sustained development spending. Domestic affordability is further strengthened by price oversight, with the NPPA stating that it fixed retail prices for 39 formulations under the Drugs Prices Control Order based on its January 2024 authority meeting, which supports medicine accessibility while shaping competitive dynamics.

For instance, Aurobindo Pharma said it manufactured more than 45 billion doses in FY24 and had 14 biosimilars in its product pipeline with 4 products in global phase 3 clinical trials, showing how India’s generics leaders are using scale and R and D depth to drive accessibility, exports, and higher value pharmaceutical innovation.

Download Free Sample Report

Key Market Challenges

Quality Control and Counterfeiting

India’s pharmaceutical market remains globally important for affordability and scale, but quality control and counterfeiting continue to be serious challenges because a vast manufacturing and distribution ecosystem makes uniform compliance harder to sustain across every batch, facility, and channel.

The concern is not theoretical, as data reported from the government’s own response in Parliament showed that out of 1.16 lakh drug samples tested in 2024 to 2025, 3,104 were found to be not of standard quality and 245 were identified as spurious or adulterated, highlighting why stronger enforcement and surveillance remain critical to patient safety and market credibility. In response, regulators have pushed traceability tools, including mandatory QR codes on 300 widely used drug brands from August 1 2023 to help verify authenticity and curb fake medicines in the domestic market.

For instance, Dr. Reddy’s said it worked closely with the Government of India on serialization guidelines, built a track and trace system from manufacture to dispensing, and reported no Class I recalls in FY24, showing how large pharmaceutical companies are investing in quality systems and digital authentication to strengthen trust, even as wider supply chain monitoring still needs to improve.

Key Market Trends

Growing Demand of Biopharmaceuticals

India’s pharmaceutical industry is undergoing a major transformation, with biopharmaceuticals emerging as a key growth driver. These include advanced therapies such as monoclonal antibodies, vaccines, and gene therapies, which offer higher precision in treating complex conditions like cancer, autoimmune disorders, and rare diseases. Unlike traditional drugs, biopharmaceuticals are derived from biological sources and require sophisticated manufacturing processes, but deliver superior therapeutic outcomes.

Rising prevalence of chronic and lifestyle-related diseases is accelerating demand for such targeted treatments. Government initiatives like the National Biopharma Mission are fostering innovation by promoting collaboration between industry, academia, and research institutions.

India’s rapidly growing biotechnology sector, supported by favorable policies and increasing R&D investments, is further strengthening this trend. The rise of biosimilars cost-effective alternatives to biologics is expanding access to advanced therapies while leveraging India’s generics expertise. With strong growth in the bioeconomy and increasing global demand, biopharmaceuticals are set to play a pivotal role in shaping India’s future pharmaceutical landscape..

Segmental Insights

Type Insights

Based on type, pharmaceutical drugs emerged as the fastest-growing segment in the India pharmaceutical market in 2024, driven by expanding healthcare needs and a rising disease burden. India’s growing population and increasing life expectancy have led to a higher prevalence of chronic conditions such as diabetes, cardiovascular diseases, and cancer, significantly boosting demand for effective drug therapies. At the same time, infectious diseases like tuberculosis and malaria continue to drive the need for pharmaceutical interventions.

The surge in non-communicable diseases (NCDs) has increased reliance on long-term treatment and disease management, further accelerating drug consumption. In response, pharmaceutical companies are investing heavily in research and development to introduce innovative therapies and improve existing treatments.

India is also advancing in generics, biosimilars, and complex formulations, strengthening its ability to serve both domestic and global markets. The development of targeted therapies and immunotherapies, particularly in oncology, is further propelling growth by addressing complex and previously difficult-to-treat conditions.

Drug Classification Insights

Based on drug classification, generic drugs are expected to dominate the India pharmaceutical market during the forecast period, driven by strong regulatory support and affordability. A key enabler has been the Indian Patents Act of 1970, which allowed domestic companies to manufacture cost-effective alternatives to branded drugs, laying the foundation for India’s leadership in the global generics market.

Rising prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions has increased the need for long-term, affordable treatment options. Generics meet this demand by offering comparable quality at significantly lower prices, making them accessible to a broader population, including India’s expanding middle class and aging demographic.

India’s generics strength extends globally, with pharmaceutical companies exporting large volumes to developed markets like the US and Europe. Continued investment in R&D has also enabled the development of complex generics and biosimilars. Along with advancements in manufacturing efficiency, this has reinforced India’s competitive advantage and sustained the dominance of generics in the pharmaceutical market.

Download Free Sample Report

Regional Insights

Based on Region, West India have emerged as the dominating region in the India Pharmaceutical Market in 2024. West India, particularly the states of Maharashtra and Gujarat, benefits from a well-developed industrial infrastructure that has significantly contributed to its dominance in the pharmaceutical market. Maharashtra, with Mumbai as its commercial hub, offers a thriving ecosystem for pharmaceutical companies. The city is home to a substantial number of multinational corporations (MNCs) and domestic pharmaceutical firms, drawn by its advanced infrastructure, availability of skilled talent, and proximity to major ports. This geographical advantage facilitates efficient import and export operations, essential for global pharmaceutical trade.

Gujarat, another key player in West India, has emerged as a pharmaceutical powerhouse due to its conducive business environment and government policies that favor industrial growth. The state government has implemented several initiatives to attract pharmaceutical investments, including offering incentives for setting up manufacturing units and research facilities. Gujarat's well-established chemical and pharmaceutical industrial parks, such as the Gujarat Industrial Development Corporation (GIDC) estates, provide companies with the necessary infrastructure and logistical support to thrive.

The presence of a strong network of research and development (R&D) facilities further cements West India’s position in the pharmaceutical sector. The region is home to numerous R&D centers and institutions that foster innovation and support pharmaceutical development. Collaboration between academia and industry in West India has led to significant advancements in drug development and manufacturing processes. The region's focus on R&D is crucial in maintaining a competitive edge in the global pharmaceutical market, particularly in the development of generic drugs and specialty pharmaceuticals.

Recent Development

• In October 2025, Eli Lilly signed an agreement with Cipla that allowed the Indian drugmaker to sell Lilly’s blockbuster weight-loss medicine in India under the separate brand name Yurpeak. Reuters said Lilly would manufacture the drug while Cipla would market it, making the arrangement a clear commercial collaboration between a global innovator and one of India’s major pharmaceutical companies. The deal mattered because it expanded Lilly’s reach in India through Cipla’s domestic market presence instead of relying only on Lilly’s own promotion and distribution channels.
• In November 2025, Novo Nordisk partnered with Emcure Pharmaceuticals to exclusively distribute and market its 2.4 mg semaglutide injection in India under the new brand name Poviztra. Reuters said the collaboration formed part of Novo Nordisk India’s strategy to broaden access to its therapies for a larger patient population in the country. This was a notable pharmaceutical development because it combined Novo Nordisk’s product pipeline with Emcure’s local commercial network to strengthen its play in India’s obesity-treatment market.
• In June 2025, India’s drug regulator approved Eli Lilly’s pre-filled Mounjaro KwikPen, adding a new delivery format for the company’s diabetes and weight-loss therapy in the country. Reuters reported that Lilly had already launched Mounjaro in India at the end of March, and the once-weekly pen was cleared in six dose strengths ranging from 2.5 mg to 15 mg. The approval was important because it gave Lilly a stronger product offering in India’s fast-growing obesity and diabetes market as other multinational and domestic drugmakers prepared competing launches.
• In February 2025, Amgen inaugurated a new technology center in southern India and said it would invest about $200 million in the site during the year. The company said the facility was set up as a technology and innovation center to strengthen the use of artificial intelligence and data science in the development of new medicines. The move stood out in India’s pharmaceutical sector because it linked a sizable local investment with next-generation drug-development capabilities rather than just a conventional market-expansion plan.

Key Market Players

• Sun Pharmaceutical Industries Limited
• Divis Laboratories Limited
• Cipla Limited
• Dr. Reddy’s Laboratories Limited
• Torrent Pharmaceutical Limited
• Zydus Lifesciences Limited
• Abbott India Limited
• Alkem Laboratories Limited
• Biocon Limited 
• Lupin Limited
• Mankind Pharma Limited
• Intas Pharmaceuticals Limited
• Piramal Enterprises Limited
• Wockhardt Limited
• Glenmark Pharma Limited

Report Scope

In this report, the India Pharmaceutical Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Pharmaceutical Market, By Type:

o Pharmaceutical Drugs

o Biologics

• India Pharmaceutical Market, By Drug Classification:

o Branded Drugs

o Generic Drugs

• India Pharmaceutical Market, By Mode of Purchase:

o Prescription-Based Drugs

o Over-the-counter Drugs

• India Pharmaceutical Market, By Distribution Channel:

o Hospital Pharmacies

o Retail Pharmacies

o Online Pharmacies

• India Pharmaceutical Market, By Region:

o North India

o East India

o West India

o South India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Pharmaceutical Market.

Available Customizations:

India Pharmaceutical Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Pharmaceutical Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]